{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Protalix Biotherapeutics, Inc.
Protalix Biotherapeutics Experiences Valuation Adjustment Amid Strong Market Performance
Protalix Biotherapeutics, Inc. has recently adjusted its valuation, with its stock price at $2.19. Over the past year, the company achieved an impressive stock return of 88.79%, outperforming the S&P 500. Key metrics include a P/E ratio of 32 and a strong return on capital employed of 38.92%.
Protalix Biotherapeutics Stock Forms Golden Cross, Signals Bullish Breakout Ahead
Protalix Biotherapeutics, Inc. recently achieved a Golden Cross, a technical event often seen as a positive indicator. The stock outperformed the S&P 500 today and has shown remarkable growth over the past year. Various technical metrics indicate a bullish sentiment, suggesting optimism about the company's future prospects.
Is Protalix Biotherapeutics, Inc. overvalued or undervalued?
As of October 17, 2025, Protalix Biotherapeutics, Inc. is considered overvalued with a P/E ratio of 32 compared to its peer Puma Biotechnology's 4.74, despite strong operational efficiency metrics, indicating that investors should be cautious before investing.
Protalix Biotherapeutics Experiences Revision in Its Stock Evaluation Amid Market Challenges
Protalix Biotherapeutics, Inc. has recently adjusted its valuation, with a P/E ratio of 32 and a price-to-book value of 2.78. The company shows strong operational efficiency, reflected in its high ROCE of 38.92%. Despite year-to-date challenges, it has demonstrated significant resilience over the past year.
Is Protalix Biotherapeutics, Inc. overvalued or undervalued?
As of October 17, 2025, Protalix Biotherapeutics, Inc. is considered overvalued with a P/E ratio of 32 compared to its peer Puma Biotechnology at 4.74, and despite a strong 1-year return of 70.64%, it has underperformed against the S&P 500's 14.08% return, leading to a valuation grade shift from very attractive to attractive.
Is Protalix Biotherapeutics, Inc. overvalued or undervalued?
As of October 17, 2025, Protalix Biotherapeutics, Inc. is considered overvalued with a P/E ratio of 32 compared to its peer Puma Biotechnology's 4.74, despite a strong one-year stock return of 70.64%, but it has underperformed the S&P 500 over the past 5 and 10 years.
Is Protalix Biotherapeutics, Inc. technically bullish or bearish?
As of September 9, 2025, Protalix Biotherapeutics, Inc. has shifted to a mildly bullish trend, supported by positive weekly indicators and a strong 1-year return of 70.64%, despite underperforming the S&P 500 over the past 5 and 10 years.
Is Protalix Biotherapeutics, Inc. overvalued or undervalued?
As of August 28, 2025, Protalix Biotherapeutics, Inc. is considered overvalued with a P/E ratio of 32 compared to its peer Puma Biotechnology's 4.74, despite a strong 70.64% return over the past year, while its long-term outlook is less favorable with a 5-year return of -49.04%.
Is Protalix Biotherapeutics, Inc. overvalued or undervalued?
As of May 9, 2025, Protalix Biotherapeutics, Inc. is considered undervalued with a favorable P/E ratio of 27.91 compared to its peers, despite a year-to-date return of -28.19%, indicating it may present a compelling investment opportunity at its current price of 1.35.
Is Protalix Biotherapeutics, Inc. technically bullish or bearish?
As of June 17, 2025, Protalix Biotherapeutics, Inc. exhibits a sideways trend with mixed signals across time frames, indicating indecision in the market and a lack of strong bullish or bearish momentum.
Who are in the management team of Protalix Biotherapeutics, Inc.?
As of March 2022, the management team of Protalix Biotherapeutics, Inc. includes Chairman Zeev Bronfeld, CEO Dror Bashan, and Directors Pol Boudes, Gwen Melincoff, Amos Bar-Shalev, David Granot, and Aharon Schwartz. They oversee the company's strategic direction and operations.
What does Protalix Biotherapeutics, Inc. do?
Protalix Biotherapeutics, Inc. is a biopharmaceutical company specializing in the development and commercialization of recombinant therapeutic proteins. As of March 2025, it reported net sales of $10 million and a net loss of $4 million, with a market cap of $109.06 million.
How big is Protalix Biotherapeutics, Inc.?
As of Jun 18, Protalix Biotherapeutics, Inc. has a market capitalization of 109.06 million, with net sales of 59.76 million and a net profit of 3.91 million over the latest four quarters. The company reported shareholder's funds of 43.21 million and total assets of 73.42 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
